Figures computed from official regulatory filings — .
Ownershipinsiders 19.7% · institutions 47.91%
In EUR · as of Oct 26, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Medios AG only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG was founded in 2015 and is headquartered in Berlin, Germany.
Market information source · Oct 26, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Stefan Bauerreis | Buy | $44.9K | conv 55First in 12mo |
| BAFIN |
| Thomas Meier | Other | $257.3K | BAFIN |
| Christoph Prusseit | Buy | $70.3K | conv 36First in 12mo | BAFIN |